Triple-negative breast cancer (TNBC), distinguished by the absence of ER, progesterone receptor (PR) and HER2 expression, comprises approximately 15% of all diagnosed breast cancers worldwide. This evidence concerns the gene PGR and triple-negative breast carcinoma.